; (2) the dollar amount of innovation prizes for different stages of research and development of different classes or types of drugs, and total annual funding, that would be necessary to stimulate investment sufficient to achieve such successful drug development and related milestones; (3) the relative effectiveness and efficiency of such alternative models in stimulating innovation, compared to the status quo that includes patents and regulatory exclusivities; (4) strategies to implement such alternative models described in paragraph (1), including a phased transition; and (5) the anticipated economic and societal impacts of such alternative models, including an assessment of impact on— (A) the number and variety of new drugs that would be developed, approved, and marketed in the United States, including such new drugs intended to prevent, diagnose, or treat a rare disease or condition; (B) the rate at which new drugs would be developed, approved, and marketed in the United States; (C) access to medication; (D) health outcomes; (E) average lifespan and disease burden in the United States; (F) the number of manufacturers that would be seeking approval for a drug or bringing a drug to market for the first time; (G) Federal discretionary and mandatory spending